Fungal mycobiome-mediated immune response: a non-negligible promoter in pancreatic oncogenesis and chemoresistance

Yaling Jiang; Valentina Donati; Godefridus J. Peters; Elisa Giovannetti; Dong Mei Deng

doi:10.20517/cdr.2023.06

Fungal mycobiome-mediated immune response: a non-negligible promoter in pancreatic oncogenesis and chemoresistance

Yaling Jiang, Valentina Donati, Godefridus J. Peters^*, Elisa Giovannetti, Dong Mei Deng^*

^*Corresponding author for this work

Preventive Dentistry

Research output: Contribution to Journal › Review article › Academic › peer-review

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal cancers in humans due to late diagnosis and poor response to treatments. The tumor microenvironment (TME) of PDAC is characterized by a distinctive, suppressive immune profile, which inhibits the protective functions of anti-tumor immunity and thereby contributes to PDAC progression. Recently, the study of Alam et al. discovered for the first time that the intratumoral fungal mycobiome could contribute to the recruitment and activation of type 2 immune cells in the TME of PDAC via enhancing the secretion of a chemoattractant, interleukin (IL-) 33. In this article, we reviewed the important findings of this study. Together with our findings, we synthetically discussed the role of the fungal mycobiome in orchestrating the immune response and thereby modulating tumor progression.

Original language	English
Pages (from-to)	284-290
Number of pages	7
Journal	Cancer Drug Resistance
Volume	6
Issue number	2
Early online date	10 May 2023
DOIs	https://doi.org/10.20517/cdr.2023.06
Publication status	Published - 2023

Bibliographical note

Funding Information:
This work was supported by grants from the Cancer Center Amsterdam (CCA) Foundation, As-sociazione Italiana per la Ricerca sul Cancro (AIRC) and Fondazione Pisana per la Scienza (FPS) to Giovannetti E, and the Dutch Research Council (NWO) (OCENW.XS22.4.135) to Jiang Y.

Publisher Copyright:
© The Author(s) 2023.

Funding

This work was supported by grants from the Cancer Center Amsterdam (CCA) Foundation, As-sociazione Italiana per la Ricerca sul Cancro (AIRC) and Fondazione Pisana per la Scienza (FPS) to Giovannetti E, and the Dutch Research Council (NWO) (OCENW.XS22.4.135) to Jiang Y.

Funders	Funder number
As-sociazione Italiana per la Ricerca sul Cancro
Fondazione Pisana per la Scienza
Nederlandse Organisatie voor Wetenschappelijk Onderzoek	OCENW.XS22.4.135
Nederlandse Organisatie voor Wetenschappelijk Onderzoek
Cancer Center Amsterdam

Keywords

chemoresistance
interleukin 33
Mycobiome
pancreatic cancer
type 2 immune cells

Access to Document

10.20517/cdr.2023.06

Persistent URL (handle)

Copy link address

Cite this

@article{c3f2b4987a0d4078a030fe8d91d5700b,

title = "Fungal mycobiome-mediated immune response: a non-negligible promoter in pancreatic oncogenesis and chemoresistance",

abstract = "Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal cancers in humans due to late diagnosis and poor response to treatments. The tumor microenvironment (TME) of PDAC is characterized by a distinctive, suppressive immune profile, which inhibits the protective functions of anti-tumor immunity and thereby contributes to PDAC progression. Recently, the study of Alam et al. discovered for the first time that the intratumoral fungal mycobiome could contribute to the recruitment and activation of type 2 immune cells in the TME of PDAC via enhancing the secretion of a chemoattractant, interleukin (IL-) 33. In this article, we reviewed the important findings of this study. Together with our findings, we synthetically discussed the role of the fungal mycobiome in orchestrating the immune response and thereby modulating tumor progression.",

keywords = "chemoresistance, interleukin 33, Mycobiome, pancreatic cancer, type 2 immune cells",

author = "Yaling Jiang and Valentina Donati and Peters, {Godefridus J.} and Elisa Giovannetti and Deng, {Dong Mei}",

note = "Funding Information: This work was supported by grants from the Cancer Center Amsterdam (CCA) Foundation, As-sociazione Italiana per la Ricerca sul Cancro (AIRC) and Fondazione Pisana per la Scienza (FPS) to Giovannetti E, and the Dutch Research Council (NWO) (OCENW.XS22.4.135) to Jiang Y. Publisher Copyright: {\textcopyright} The Author(s) 2023.",

year = "2023",

doi = "10.20517/cdr.2023.06",

language = "English",

volume = "6",

pages = "284--290",

journal = "Cancer Drug Resistance",

issn = "2578-532X",

publisher = "OAE Publishing Inc.",

number = "2",

}

TY - JOUR

T1 - Fungal mycobiome-mediated immune response

T2 - a non-negligible promoter in pancreatic oncogenesis and chemoresistance

AU - Jiang, Yaling

AU - Donati, Valentina

AU - Peters, Godefridus J.

AU - Giovannetti, Elisa

AU - Deng, Dong Mei

N1 - Funding Information: This work was supported by grants from the Cancer Center Amsterdam (CCA) Foundation, As-sociazione Italiana per la Ricerca sul Cancro (AIRC) and Fondazione Pisana per la Scienza (FPS) to Giovannetti E, and the Dutch Research Council (NWO) (OCENW.XS22.4.135) to Jiang Y. Publisher Copyright: © The Author(s) 2023.

PY - 2023

Y1 - 2023

N2 - Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal cancers in humans due to late diagnosis and poor response to treatments. The tumor microenvironment (TME) of PDAC is characterized by a distinctive, suppressive immune profile, which inhibits the protective functions of anti-tumor immunity and thereby contributes to PDAC progression. Recently, the study of Alam et al. discovered for the first time that the intratumoral fungal mycobiome could contribute to the recruitment and activation of type 2 immune cells in the TME of PDAC via enhancing the secretion of a chemoattractant, interleukin (IL-) 33. In this article, we reviewed the important findings of this study. Together with our findings, we synthetically discussed the role of the fungal mycobiome in orchestrating the immune response and thereby modulating tumor progression.

AB - Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal cancers in humans due to late diagnosis and poor response to treatments. The tumor microenvironment (TME) of PDAC is characterized by a distinctive, suppressive immune profile, which inhibits the protective functions of anti-tumor immunity and thereby contributes to PDAC progression. Recently, the study of Alam et al. discovered for the first time that the intratumoral fungal mycobiome could contribute to the recruitment and activation of type 2 immune cells in the TME of PDAC via enhancing the secretion of a chemoattractant, interleukin (IL-) 33. In this article, we reviewed the important findings of this study. Together with our findings, we synthetically discussed the role of the fungal mycobiome in orchestrating the immune response and thereby modulating tumor progression.

KW - chemoresistance

KW - interleukin 33

KW - Mycobiome

KW - pancreatic cancer

KW - type 2 immune cells

UR - http://www.scopus.com/inward/record.url?scp=85164516779&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85164516779&partnerID=8YFLogxK

U2 - 10.20517/cdr.2023.06

DO - 10.20517/cdr.2023.06

M3 - Review article

AN - SCOPUS:85164516779

SN - 2578-532X

VL - 6

SP - 284

EP - 290

JO - Cancer Drug Resistance

JF - Cancer Drug Resistance

IS - 2

ER -

Fungal mycobiome-mediated immune response: a non-negligible promoter in pancreatic oncogenesis and chemoresistance

Abstract

Bibliographical note

Funding

Keywords

Access to Document

Persistent URL (handle)

Other files and links

Fingerprint

Cite this